News Release Details
The collaboration will increase access to screening, enabling medical providers to identify and treat behavioral health conditions at scale
Developed with NeuroFlow, a key collaborator in Magellan’s digital transformation, this solution will increase access to behavioral health screening and care by enabling primary care and specialty providers to identify and manage undertreated and underdiagnosed low- to moderate-risk behavioral health conditions before they escalate.
Providers will receive enhanced support from Magellan’s clinical team which will leverage NeuroFlow’s cloud-based platform to offer:
- Ease of communication with members and their care team
- Patient data integrated into electronic medical records and existing provider practice workflows
- Artificial intelligence which identifies at-risk members, enables real-time feedback and reports on outcomes such as symptom reduction and remission
- Integration with a member app that provides engaging self-care activities and personalized clinical content, feeding patient-recorded outcomes to a registry for monitoring and risk stratification
This high-tech and high-touch solution addresses the growing challenge of limited access to and availability of providers. According to a report from the New American Economy, 60% of the counties in the
“Too many Americans live in behavioral health deserts – they have little or no access to care. Or, at best, they have access to a fragmented healthcare system, leaving key needs unmet,” said
The Collaborative Care Model
Collaborative care is an evidence-based integrated care model that provides delivery systems with a population health and team-based approach to treating patients with behavioral health and co-morbid medical conditions within the primary care setting.
The collaborative care model deploys teams of tech-enabled care managers and consulting psychiatrists to help primary care practices integrate behavioral healthcare into the primary care setting. It is a virtual practice overlay and has been proven to enhance the effectiveness of depression care, while also helping to deliver a 6:1 return on investment to providers.
While the clinical effectiveness of collaborative care is backed by years of research, it traditionally comes with high costs and a long ramp-up time. Magellan’s solution uses NeuroFlow’s technology to address those barriers, enabling efficient deployment and integration of services across large populations, in a matter of days to weeks.
How Magellan’s CoCM Solution Works
Patients complete validated behavioral health assessments using a mobile device or tablet when they arrive at their provider’s office. Screening results are analyzed and delivered to the dashboard embedded in the patient’s electronic health record. The provider is able to discuss the results with the patient during the visit and recommend collaborative care management to those who are at risk.
A Magellan care manager leverages NeuroFlow’s cloud-based registry to monitor their patient panel and prioritize those in need of immediate support. The care manager serves as a liaison between the provider and the Magellan psychiatric consultant who recommends the best course of action. The patient benefits from NeuroFlow’s evidence-based clinical content during and after treatment to manage their condition through activities such as journaling and psychoeducation. The use of gamification within the app also keeps patients engaged.
“We are proud to work with Magellan to bring this solution to market and address the growing need for behavioral healthcare services,” said
About NeuroFlow: NeuroFlow is a digital health company combining workflow automation, consumer engagement solutions, and applied AI to promote behavioral health integration in all care settings. NeuroFlow’s suite of HIPAA-compliant, cloud-based tools simplify remote patient monitoring, enable risk stratification, and facilitate collaborative care. With NeuroFlow, health care organizations can finally bridge the gap between mental and physical health in order to improve outcomes and reduce the cost of care. http://www.neuroflow.com.
This press release includes statements which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events that may not prove to be accurate. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included within the Company’s most recent Annual Report on Form 10-K, quarterly report on Form 10-Q, and subsequent reports on Forms 10-Q and 8-K. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.